All studies
RecruitingTherapeutic exploratory (Phase II)Interventional

A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based therapy.

This clinical trial is studying a medicine called imetelstat in adults with acute myeloid leukaemia (AML) or higher-risk myelodysplastic syndromes (MDS). Both are serious conditions affecting how the bone marrow makes healthy blood cells. Standard care usually involves medicines known as hypomethylating agents (HMAs). However, these drugs do not work for everyone, or they can stop working over time. When this happens, doctors need new, effective options. In this study, participants receive imetelstat alongside medicines to prevent allergic reactions (hydrocortisone and diphenhydramine). Doctors will check how well the cancer responds after four months of treatment. They will also track side effects, survival times, and how participants feel in their daily lives using quality-of-life questionnaires. The goal is to see if imetelstat is safe and helpful for people who have run out of standard treatment options.

At a glance

Status
Recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Gcp-Service International West GmbH
Enrolment target
30
Start
26 Apr 2023

What is this study about?

Acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) are blood disorders that begin in the bone marrow, the spongy centre of bones where blood cells are made. In these conditions, the body produces faulty, immature blood cells instead of healthy red cells, white cells, and platelets. This can leave people feeling very tired, prone to infections, and at risk of easy bruising or bleeding. Higher-risk MDS can also progress into AML over time.

For many patients, standard treatment involves a group of medicines called hypomethylating agents, or HMAs. While these medicines can keep the disease under control for a period, they do not cure it. In many cases, the disease either resists the treatment from the start or returns after a while. When standard HMAs stop working, there are very few proven treatment options left, making new approaches urgently needed.

This trial investigates an experimental drug called imetelstat. Cancer cells often rely on a special enzyme called telomerase to keep dividing and avoid dying off. Imetelstat is designed to block this enzyme, which may slow down or stop the growth of abnormal blood cells. To keep patients safe and comfortable, the study also uses standard medicines, including hydrocortisone and diphenhydramine, before treatment to help prevent allergic reactions to the drip.

By taking part, participants help doctors learn whether imetelstat can shrink the disease, clear faulty cells from the bone marrow, and help people live longer. The study also measures participants' quality of life to see whether the treatment helps them maintain their energy, comfort, and day-to-day activities.

Key takeaways

  • Testing a new drug, imetelstat, for adults with AML or high-risk MDS.
  • Aimed at people whose disease did not respond to standard HMA therapy.
  • The main goal is to measure how well the disease responds after 4 months.
  • Medicines are given before each infusion to prevent allergic reactions.
  • Participation includes close monitoring, regular hospital visits, and quality-of-life checks.

Who may be eligible?

This trial is open to adults aged 18 and older who have been diagnosed with either acute myeloid leukaemia (AML) or higher-risk myelodysplastic syndromes (MDS).

To be considered, you must have already received standard treatment with a hypomethylating agent (such as azacitidine or decitabine), and that treatment must have either stopped working or failed to control your condition.

Because this is an intensive trial, you must also be well enough to attend regular hospital appointments and have adequate organ function, such as reasonably healthy kidneys and liver. Your hospital haematology team will carry out detailed blood and bone marrow tests to confirm whether this study is safe and suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with acute myeloid leukaemia (AML) or high-risk MDS.
  3. I have already tried standard hypomethylating agent (HMA) treatment.
  4. My previous treatment has stopped working or did not clear the disease.
  5. I am well enough to attend regular hospital visits for infusions and tests.
Answer every question to see your result.

What does participation involve?

Taking part involves regular visits to a hospital clinic or clinical trial centre. You will receive imetelstat as an infusion (a slow drip into a vein). Before each dose, you will receive two standard medicines, hydrocortisone and diphenhydramine, to reduce the chance of side effects or allergic reactions during the infusion.

Throughout the study, your medical team will monitor you closely. This involves regular blood tests, physical checks, and periodic bone marrow biopsies to see how the disease is responding. You will also be asked to complete short questionnaires about your energy levels, symptoms, and day-to-day well-being.

The main check to see if the treatment is working takes place around four months (17 weeks) after starting. If the drug is helping and you are tolerating it well, you may continue taking it for longer. After treatment finishes, the research team will keep in touch to check on your health and recovery.

Potential risks and benefits

A potential benefit of joining this study is getting access to a new treatment when standard medicines are no longer working, along with very close care from a specialist team. However, there is no guarantee that imetelstat will improve your condition. Like all cancer treatments, imetelstat can cause side effects, which may include lower blood cell counts, tiredness, nausea, or reactions to the drip. Your care team will monitor you carefully to manage any problems quickly. Joining the trial is entirely your choice, and you can withdraw at any time without your regular NHS care being affected.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France
  • —
    Unverified
    Germany

Common questions

What is imetelstat and how does it work?

Imetelstat is an experimental medicine that blocks telomerase, an enzyme that cancer cells rely on to survive and multiply. By targeting this enzyme, the drug aims to stop abnormal blood cells from growing.

Will I receive a dummy drug (placebo)?

No. This is a phase 2 study where all participants receive the active study medicine, imetelstat. There is no placebo group.

Why do I need hydrocortisone and diphenhydramine?

These are common medicines given before your infusion to prevent allergic reactions, itching, or fever that can sometimes happen when receiving new drugs through a drip.

How often will I need bone marrow tests?

Bone marrow tests are needed before you start and at key points during treatment, including around the four-month mark, to see if the drug is clearing abnormal cells.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary. You can choose to stop taking the study drug at any point, and your doctors will discuss other supportive care options with you.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "A phase II study evaluating the efficacy and safety of IMete…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.